Cancer Genomics

Pathway Genomics and Health Related Genetic Testing

Offering genetic testing direct to consumers is big business, with both 23andMe and doing very well for themselves as a result. Offering ancestry genetic tests direct to the consumer is one thing, but offering genetic testing for health reasons is an entirely different animal. A few years ago, 23andMe had to suspend all health-related […]

Why is Foundation Medicine up +95%?

In a July 2013 article, we highlighted the proposed IPO of a cancer genomics company called Foundation Medicine (NASDAQ:FMI). Their flagship product, FoundationOne, provides a fully informative genomic profile obtained from a tumor sample which helps physicians make treatment decisions for patients with cancer. By identifying the molecular growth drivers of their cancers, the oncologists can then […]

myRisk: Test Yourself for 8 Hereditary Cancers

In a recent article, we discussed a hereditary breast cancer test for women called the BRACAnalysis. Statistically, it seems that the majority of women would not benefit from taking this test. The BRACAnalysis genetic test is the leading revenue stream for the company that sells it, Myriad Genetics (NASDAQ:MYGN), but has been sharply decreasing over […]

Should Women Take the BRACAnalysis Test?

In previous articles, we discussed cancer testing companies such as Raindance Technologies and Sysmex Inostics that can help identify cancer at the earliest stages in order to allow for early treatment. Other companies like Foundation Medicine can interrogate the entire coding sequence of 236 cancer-related genes which will allow a physician to create personalized cancer treatments for […]

MDxHealth Improves Prostate Cancer Biopsies

According to the Prostate Cancer Foundation, prostate cancer is the most common non-skin cancer in America, affecting 1 in 6 men. One new case occurs every 2.3 minutes and a man dies from prostate cancer every 16 minutes. It is estimated that there are more than 2.5 million American men currently living with prostate cancer. One of the […]

Is Guardant Health a Threat to Foundation Medicine?

Sysmex Inostics and Apocell are companies that are looking to provide the ability to test for cancer via a simple blood test which is a promising potential market. Foundation Medicine (NASDAQ:FMI), is looking to address the emerging cancer genomics market by providing a service in which using a biopsy, Foundation can interrogate the entire coding sequence of 236 cancer-related genes. The […]

6 things to like about Foundation Medicine’s Proposed IPO

In an earlier article we discussed the June IPO of Nanostring, an oncology company using microfluidics to test for the risk of recurrence for breast cancer. Another interesting oncology company that filed for IPO on July 29th 2013 is Foundation Medicine. About Foundation Medicine Foundation Medicine is involved in cancer genomics, that is examining the genetic […]